Megadose bromazepam dependence

Area of Science:

• Pharmacology
• Neuroscience
• Clinical Medicine

Background:

• Benzodiazepines (BZDs) are widely prescribed but carry risks of tolerance and dependence.
• Chronic BZD use is linked to cognitive impairment, falls, accidents, and dependence.
• Recommendations for limited BZD use are often disregarded.

Purpose of the Study:

• To evaluate the effects of extremely high-dose bromazepam on a patient's psychological and physiological status.
• To assess cognitive function, anxiety, depression, sleep patterns, and cerebral metabolism under chronic high-dose BZD exposure.

Main Methods:

• A case study of a 37-year-old woman on 220 mg daily bromazepam.
• Psychological assessment using questionnaires for anxiety, depression, and cognition.
• Polysomnography for sleep apnea and daytime sleepiness evaluation.
• Cerebral Positron Emission Tomography (PET) scan for metabolic activity.

Main Results:

• Bromazepam blood concentration reached 7800 μg/L (15 times the toxic dose).
• Patient reported significant anxiety and depression, but only moderate cognitive impairment.
• Sleep study revealed normal oxygen saturation, minimal respiratory events, and moderate sleepiness (9 min latency).
• Cerebral PET scan showed slightly reduced but homogeneous cortical glucose metabolism.

Conclusions:

• Anxiety persisted despite high bromazepam dosage.
• Cognition, sleepiness, respiratory function, and brain metabolism remained surprisingly close to normal.
• This case highlights potential resilience or compensatory mechanisms in some individuals under extreme BZD exposure.